Thomas Eugène

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT

Thomas Carlier, Thomas Eugène, Caroline Bodet‐Milin et al. · EJNMMI Research · 2013 · 84 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas

Thomas Eugène, Nadège Corradini, Thomas Carlier et al. · Nuclear Medicine Communications · 2012 · 75 citations

Medicine, Oncology, Radiology +17

90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

Patrice Chevallier, Thomas Eugène, Nelly Robillard et al. · The Lancet Haematology · 2015 · 44 citations

Medicine, Hematology, Oncology +16

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

Clément Bailly, Thomas Carlier, Bastien Jamet et al. · Clinical Cancer Research · 2018 · 30 citations · Full text

Medicine, Nuclear Medicine, Oncology +15